Historical Valuation
XBiotech Inc (XBIT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.15 is considered Undervalued compared with the five-year average of 22.86. The fair price of XBiotech Inc (XBIT) is between 882.46 to 884.33 according to relative valuation methord. Compared to the current price of 2.56 USD , XBiotech Inc is Undervalued By 99.71%.
Relative Value
Fair Zone
882.46-884.33
Current Price：2.56
99.71%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
XBiotech Inc (XBIT) has a current Price-to-Book (P/B) ratio of 0.43. Compared to its 3-year average P/B ratio of 0.70 , the current P/B ratio is approximately -37.63% higher. Relative to its 5-year average P/B ratio of 0.85, the current P/B ratio is about -49.01% higher. XBiotech Inc (XBIT) has a Forward Free Cash Flow (FCF) yield of approximately -32.86%. Compared to its 3-year average FCF yield of -18.67%, the current FCF yield is approximately 76.01% lower. Relative to its 5-year average FCF yield of -8.88% , the current FCF yield is about 270.31% lower.
P/B
Median3y
0.70
Median5y
0.85
FCF Yield
Median3y
-18.67
Median5y
-8.88
Competitors Valuation Multiple
AI Analysis for XBIT
The average P/S ratio for XBIT competitors is 222.57, providing a benchmark for relative valuation. XBiotech Inc Corp (XBIT.O) exhibits a P/S ratio of 0.15, which is -99.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for XBIT
1Y
3Y
5Y
Market capitalization of XBIT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of XBIT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is XBIT currently overvalued or undervalued?
XBiotech Inc (XBIT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.15 is considered Undervalued compared with the five-year average of 22.86. The fair price of XBiotech Inc (XBIT) is between 882.46 to 884.33 according to relative valuation methord. Compared to the current price of 2.56 USD , XBiotech Inc is Undervalued By 99.71% .
What is XBiotech Inc (XBIT) fair value?
XBIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of XBiotech Inc (XBIT) is between 882.46 to 884.33 according to relative valuation methord.
How does XBIT's valuation metrics compare to the industry average?
The average P/S ratio for XBIT's competitors is 222.57, providing a benchmark for relative valuation. XBiotech Inc Corp (XBIT) exhibits a P/S ratio of 0.15, which is -99.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for XBiotech Inc (XBIT) as of Jan 10 2026?
As of Jan 10 2026, XBiotech Inc (XBIT) has a P/B ratio of 0.43. This indicates that the market values XBIT at 0.43 times its book value.
What is the current FCF Yield for XBiotech Inc (XBIT) as of Jan 10 2026?
As of Jan 10 2026, XBiotech Inc (XBIT) has a FCF Yield of -32.86%. This means that for every dollar of XBiotech Inc’s market capitalization, the company generates -32.86 cents in free cash flow.
What is the current Forward P/E ratio for XBiotech Inc (XBIT) as of Jan 10 2026?
As of Jan 10 2026, XBiotech Inc (XBIT) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of XBiotech Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for XBiotech Inc (XBIT) as of Jan 10 2026?
As of Jan 10 2026, XBiotech Inc (XBIT) has a Forward P/S ratio of 0.15. This means the market is valuing XBIT at $0.15 for every dollar of expected revenue over the next 12 months.